WALTHAM, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its second quarter 2026 financial results on Tuesday, July 28, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended June 30, 2026.
The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 768981187. In addition, a webcast will be accessible via the
Investor Relations
section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the
Investor Relations
section of the Company’s website.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are
“inspiring advances in bioprocessing”
for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at
www.repligen.com
, and follow us on
LinkedIn
.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
View the Zacks #1 Rank List
Repligen Corporation to Report Second Quarter 2026 Financial Results on July 28, 2026
Repligen Corporation will announce Q2 2026 financial results and host a conference call on July 28, 2026.
Quiver AI Summary
Repligen Corporation has announced that it will release its second quarter 2026 financial results on July 28, 2026, with a press release issued before market opening. A conference call will be held at 8:00 a.m. ET to discuss the results for the period ending June 30, 2026, accessible via phone and through a webcast on the Company's website. Repligen, headquartered in Waltham, Massachusetts, specializes in innovative bioprocessing technologies for the biopharmaceutical sector, focusing on various areas such as Filtration, Chromatography, and Process Analytics. The press release contains forward-looking statements and advises investors of potential risks that may affect actual results.
Potential Positives
Potential Negatives
FAQ
When will Repligen release its Q2 2026 financial results?
Repligen will report its second quarter 2026 financial results on Tuesday, July 28, 2026.
What time is the conference call for financial results?
The conference call will be held at 8:00 a.m. ET on July 28, 2026.
How can I access the conference call?
Call toll-free at (833) 461-5787 for domestic callers or (585) 542-9983 for international callers.
Where can I find the live webcast of the call?
The webcast will be available in the Investor Relations section of Repligen's website.
What does Repligen Corporation specialize in?
Repligen develops and commercializes innovative bioprocessing technologies for manufacturing biological drugs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RGEN Insider Trading Activity
$RGEN insiders have traded $RGEN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $RGEN stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RGEN Revenue
$RGEN had revenues of $194.3M in Q1 2026. This is an increase of 14.83% from the same period in the prior year.
You can track RGEN financials on Quiver Quantitative's RGEN stock page.
You can access data on RGEN stock through the Quiver Quantitative API.
$RGEN Hedge Fund Activity
We have seen 213 institutional investors add shares of $RGEN stock to their portfolio, and 182 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$RGEN Analyst Ratings
Wall Street analysts have issued reports on $RGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
To track analyst ratings and price targets for $RGEN, check out Quiver Quantitative's $RGEN forecast page.
$RGEN Price Targets
Multiple analysts have issued price targets for $RGEN recently. We have seen 12 analysts offer price targets for $RGEN in the last 6 months, with a median target of $160.0.
Here are some recent targets:
Full Release
WALTHAM, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its second quarter 2026 financial results on Tuesday, July 28, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended June 30, 2026.
The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 768981187. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com , and follow us on LinkedIn .
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
Read full article here »